Join Amanda Mixon, PA-C, President of RhAPP and a practicing physician assistant in Northern Colorado, as she highlights the critical role of early detection and management in lupus nephritis. With up to 50% of lupus patients developing kidney involvement, proactive screening and timely intervention are essential to preventing severe complications, including end-stage renal disease (ESRD).

Lupus nephritis results from autoantibody-driven kidney inflammation, leading to proteinuria, hypertension, and progressive kidney damage. Without proper management, up to 30% of patients face a 10-year mortality rate, while 10-20% may progress to ESRD. The latest American College of Rheumatology (ACR) guidelines emphasize routine urine protein screening every six to twelve months for lupus patients, with more frequent monitoring in those with known kidney disease. Patients who fail to achieve complete renal response should have kidney function and protein levels checked at least every three months, with biopsy considered for persistent proteinuria or unexplained kidney function decline.

By following updated screening recommendations and initiating treatment early, clinicians can help preserve kidney function and improve long-term outcomes.

Stay informed on the latest lupus nephritis research, treatment strategies, and expert discussions by visiting RhAPP.org or accessing educational content on the RhAPP ACE App.